Piperazine designer drugs of abuse
- 1 April 2007
- journal article
- editorial
- Published by Elsevier in The Lancet
- Vol. 369 (9571) , 1411-1413
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Collapse, reported seizure—and an unexpected pillThe Lancet, 2007
- Metabolism of Designer Drugs of AbuseCurrent Drug Metabolism, 2005
- N-Substituted Piperazines Abused by Humans Mimic the Molecular Mechanism of 3,4-Methylenedioxymethamphetamine (MDMA, or ‘Ecstasy’)Neuropsychopharmacology, 2004
- A2 (N-Benzylpiperazine) a New Drug of Abuse in SwedenJournal of Analytical Toxicology, 2004
- Position of chromatographic techniques in screening for detection of drugs or poisons in clinical and forensic toxicology and/or doping controlClinical Chemistry and Laboratory Medicine (CCLM), 2004
- Screening for and validated quantification of amphetamines and of amphetamine‐ and piperazine‐derived designer drugs in human blood plasma by gas chromatography/mass spectrometryJournal of Mass Spectrometry, 2003
- Tödliches Hirnödem nach Einnahme von Ecstasy und BenzylpiperazinDMW - Deutsche Medizinische Wochenschrift, 2001
- Serotonin syndrome after challenge with the 5-HT agonist meta-chlorophenylpiperazinePsychiatry Research, 1998